Passive Detection- SARS-CoV-2 (COVID-19) A&M Breathalyzer (PROTECT Kiosk) for Operational Medicine

Launched by THE GENEVA FOUNDATION · May 3, 2024

Keywords

ClinConnect Summary

This clinical trial is exploring a new device called the A&M Breathalyzer PROTECT Kiosk, which is designed to detect COVID-19 through breath samples. Researchers want to see how well this device can identify both symptomatic and asymptomatic individuals who might be carrying the SARS-CoV-2 virus, the virus that causes COVID-19. The goal is to make the breathalyzer more effective for use in military and other operational settings by testing it at the Brooke Army Medical Center. This trial is being led by Dr. Michael Morris and Dr. Tony Yuan, who will work together to improve the technology and ensure it works accurately.

To participate in this study, you need to be at least 18 years old and undergoing standard COVID-19 testing at the medical center, whether or not you have a confirmed diagnosis. The study is open to anyone who can understand the consent process and is able to provide a breath sample. Participants can expect to undergo a breath test that lasts about 8 seconds. It's important to know that individuals under 18, or those who cannot comply with the study procedures, are not eligible to participate. This research aims to improve COVID-19 detection methods, which could ultimately help in managing the spread of the virus.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Asymptomatic and symptomatic individuals 18 years and older
• • Receiving standard COVID-19 screening and testing at BAMC
• • Do not have to be diagnosed with SARS-CoV-19 (COVID-19) but only be screened
• • Ability to understand consent
• Exclusion Criteria:
• • Any individual under age of 18
• • Anyone unable to comply (or be assisted) with study procedures
• • Anyone not able to provide temperature thermal scan, and/or perform exhaled breath for approximately 8 seconds